

DR. REDDY'S LABORATORIES LIMITED
PART I : STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2013

All amounts in Indian Rupees lakhs, except share data

Sl. No.	Particulars	Quarter ended		Year ended	
		30.06.2013	31.03.2013	30.06.2012	31.03.2013
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income from operations				
	a) Net sales / income from operations (Net of excise duty)	178,346	216,090	174,755	807,434
	b) License fees and service income	783	7,240	3,646	17,033
	c) Other operating income	3,033	12,918	2,053	18,934
	Total income from operations (net)	182,162	236,248	180,454	843,401
2	Expenses				
	a) Cost of materials consumed	56,119	63,393	50,528	234,102
	b) Purchase of traded goods	9,224	9,707	9,003	39,308
	c) Changes in inventories of finished goods, work-in-progress and	(7,919)	7,330	(7,140)	(10,073)
	d) Employee benefits expense	28,067	30,343	26,095	113,812
	e) Research and development expenses	18,516	18,505	14,025	65,092
	f) Selling expenses	19,454	17,318	19,573	76,684
	g) Depreciation and amortisation	8,909	8,463	7,312	31,285
	h) Provision for decline in the value of long-term investments	2,449	13	-	2,232
	i) Other expenditure	40,946	32,695	40,569	123,677
	Total expenses	175,765	187,767	159,965	676,119
3	Profit from ordinary activities before other income, finance costs and	6,397	48,481	20,489	167,282
4	Other income	3,331	8,879	3,040	14,171
5	Profit from ordinary activities before finance costs and	9,728	57,360	23,529	181,453
6	Finance costs	1,392	1,760	1,722	6,140
7	Profit from ordinary activities before exceptional items (5 - 6)	8,336	55,600	21,807	175,313
8	Exceptional items	-	-	-	-
9	Profit from ordinary activities before tax (7 + 8)	8,336	55,600	21,807	175,313
10	Tax expense	1,850	17,785	4,041	48,766
11	Net Profit from ordinary activities after tax (9 - 10)	6,486	37,815	17,766	126,547
12	Extra-ordinary items (net of tax)	-	-	-	-
13	Net profit for the period / year (11 - 12)	6,486	37,815	17,766	126,547
14	Paid-up equity share capital (face value Rs. 5/- each)	8,503	8,492	8,490	8,492
15	Reserves (excluding revaluation reserve)				769,869
16	Earnings per share before and after extra-ordinary items (in Rupees) per				
	Rs. 5/- share				
	- Basic	3.82	22.27	10.47	74.54
	- Diluted	3.80	22.16	10.41	74.17
		(Not annualised)	(Not annualised)	(Not annualised)	

See accompanying notes to the financial results

DR. REDDY'S LABORATORIES LIMITED
PART II : SELECTED INFORMATION FOR THE QUARTER ENDED 30 JUNE 2013

A PARTICULARS OF SHAREHOLDING

Sl No.	Particulars	Quarter ended			Year ended
		30.06.2013	31.03.2013	30.06.2012	31.03.2013
1	Public shareholding*				
	- Number of shares (face value Rs.5/- each)	97,484,533	97,799,433	97,877,295	97,799,433
	- Percentage of shareholding	57.32	57.59	57.64	57.59
2	Promoters and promoter group shareholding				
	a) Pledged / Encumbered				
	- Number of shares	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-
	b) Non-encumbered				
	- Number of shares	43,417,812	43,417,812	43,417,812	43,417,812
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	25.53	25.56	25.57	25.56

*Public shareholding as defined under Clause 40A of Listing Agreement (excludes shares held by Promoters, Promoter Group and American Depository Receipt Holders)

B INVESTOR COMPLAINTS

Pending at the beginning of the quarter	Nil
Received during the quarter	4
Disposed off during the quarter	4
Remaining unresolved at the end of the quarter	Nil

Segment Information

Sl No.	Particulars	Quarter ended			Year ended
		30.06.2013	31.03.2013	30.06.2012	31.03.2013
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Segment wise revenue, results and capital employed:				
	Segment revenue :				
	a) Pharmaceutical Services and Active Ingredients	56,878	91,781	57,019	296,136
	b) Global Generics	135,721	153,102	133,901	600,894
	c) Proprietary Products	3	332	2,779	3,037
	Total	192,602	245,215	193,699	900,067
	Less: Inter segment revenue	10,151	14,116	13,100	55,845
	Add : Other unallocable Income	3,042	14,027	2,895	13,350
	Total income	185,493	245,126	183,494	857,572
	2	Segment results :			
Profit / (loss) before tax and interest from each segment					
a) Pharmaceutical Services and Active Ingredients		4,037	12,860	6,039	36,189
b) Global Generics		44,591	45,394	35,369	187,215
c) Proprietary Products		(5,029)	(3,325)	(1,514)	(12,732)
Total		43,599	54,929	39,894	210,672
Less: (i) Interest		1,392	1,760	1,722	6,140
(ii) Other un-allocable expenditure, net		33,871	(2,431)	16,365	29,219
Total profit before tax		8,336	55,600	21,807	175,313
3		Capital Employed :			
	a) Pharmaceutical Services and Active Ingredients	250,491	255,427	208,866	255,427
	b) Global Generics	417,336	388,826	299,262	388,826
	c) Proprietary Products	(1,137)	(435)	(1,736)	(435)
	d) Unallocated	107,494	134,543	173,113	134,543
Total	774,184	778,361	679,505	778,361	

Global Generics includes operations of Biologics business. Inter-segment revenue represents sale from Pharmaceutical Services and Active Ingredients to Global Generics at cost.

Notes:

- The unaudited results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meeting held on 30 July 2013.
- The results for the quarter ended 30 June 2013 have been subjected to a "Limited review" by the Statutory Auditors of the Company. An unqualified report has been issued by them thereon.

By order of the Board
For Dr. Reddy's Laboratories Limited

Place: Hyderabad
Date: 30 July 2013

Satish Reddy
Vice Chairman & Managing Director